Pharmacokinetics of Oral Haloperidol
Oral haloperidol demonstrates rapid absorption with peak plasma concentrations occurring at approximately 4-5 hours post-ingestion, an oral bioavailability of 60-65% due to extensive first-pass metabolism, and a mean elimination half-life of approximately 18-20 hours, though this can range widely from 8.5 to 66.6 hours among individuals 1, 2, 3.
Absorption
- Onset and Peak: Haloperidol is rapidly absorbed from the gastrointestinal tract, with clinical effects beginning within 30 minutes of oral administration 2
- Peak Plasma Concentration: Achieved at a mean of 4.5 hours (range 3-6 hours) after oral dosing 1, 4
- Lag Time: A mean lag time of approximately 1.3 hours has been observed in psychiatric patients, with an absorption half-life of 1.9 hours 4
- Food Effects: Both absorption and bioavailability may increase after meals, though this is not consistently clinically significant 2
Bioavailability and First-Pass Metabolism
- Oral Bioavailability: Ranges from 60-65% (mean 0.64), indicating substantial first-pass hepatic metabolism 5, 2, 3
- First-Pass Effect: Approximately 35-40% of the oral dose is metabolized before reaching systemic circulation 5
- Hepatic Extraction Ratio: Intermediate at 0.37, meaning haloperidol clearance can be affected by changes in hepatic blood flow, enzyme activity, and protein binding 4
Distribution
- Volume of Distribution: Large at steady state (Vdss = 7.9 ± 2.5 L/kg), indicating extensive tissue distribution 4
- Plasma Protein Binding: Low plasma protein binding, which contributes to its pharmacokinetic characteristics 2
- Blood-to-Plasma Ratio: Approximately 0.79, which is important for calculating blood clearance 4
Metabolism
- Primary Pathway: Undergoes reversible oxidation/reduction metabolism to reduced haloperidol, which is biologically inactive 2
- Metabolic Variability: Significant interindividual variability exists in haloperidol reductive capacity, though reduction accounts for only a small portion of first-pass metabolism 5
- Enterohepatic Recycling: Variable extent of enterohepatic recycling contributes to interindividual pharmacokinetic differences 2
- Hepatic Clearance: Mean blood clearance is 550 ± 133 mL/min (or approximately 21.7 L/h) 4, 5
Elimination
Half-Life:
Clearance Changes: Body clearance decreases (though not significantly) with chronic dosing, while elimination half-life increases significantly 1
Steady-State Characteristics
- Time to Steady State: Typically achieved after multiple doses over several days, given the 18-20 hour half-life
- Steady-State Variability: Intrapatient coefficients of variation range from 2-72% (mean 26.4%), indicating some fluctuation even at steady state 1
- Predictive Value: An 8-hour post-dose concentration of ≤4 ng/mL after a single oral dose of 0.2 mg/kg strongly predicts patients who will not accumulate haloperidol above the therapeutic range (5-15 ng/mL) during chronic dosing 1
Clinical Implications
Large interindividual variability exists in haloperidol pharmacokinetics, but intraindividual variability is relatively stable 2. This variability can be partially explained by:
- Differences in the reversible oxidation/reduction metabolic pathway
- Variable enterohepatic recycling
- Ethnic differences in metabolism 2
- Drug interactions affecting CYP3A4 and CYP2D6 enzymes 6
Important drug interactions 6:
- Strong inducers (carbamazepine, phenobarbital, phenytoin, rifampin) require dose-correction factors of 2-5 and should generally be avoided
- Smoking acts as a weak inducer (dose-correction factor 1.2)
- Fluvoxamine and combinations of CYP3A4 and CYP2D6 inhibitors should be avoided
The therapeutic plasma concentration range is generally 4-25 μg/L (some sources suggest 5-15 ng/mL as optimal) 2.